Tracking delayed ischemic neurological deficits in people with aneurysmal subarachnoid hemorrhage — real-world data

Delayed Ischemic Neurological Deficit in Patients With Aneurysmal Subarachnoid Hemorrhage: Real World Study (DINDaSAH)

This project will collect real-world monitoring and treatment information to see how often delayed ischemic neurological deficits (DIND) happen and what diagnostic and treatment approaches people with aneurysmal subarachnoid hemorrhage receive.

Quick facts

• Study type: Observational
• Enrollment: 10000 (estimated)
• Ages: 18 Years to 90 Years
• Sex: All
• Sponsor: Xuanwu Hospital, Beijing (Academic / other)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT07160088 on ClinicalTrials.gov

What this trial studies

This is a prospective, multicenter observational effort enrolling adults admitted to the ICU with aneurysmal subarachnoid hemorrhage. It will record neurological exam findings, instrument monitoring changes, diagnostic methods, and the treatments used when delayed ischemic neurological deficits occur. The study will describe the incidence of DIND and compare real-world diagnostic and treatment patterns across centers. No investigational interventions are assigned and patient care follows local clinical practice.

Who should consider this trial

Good fit: Adults aged 18 or older admitted to the ICU with aneurysmal subarachnoid hemorrhage confirmed by cerebral CT angiography or cerebral vessel angiography who can provide informed consent.

Not a fit: People with subarachnoid hemorrhage not caused by a ruptured cerebral aneurysm (for example traumatic SAH, AVM-related, or tumor-related bleeding) are not eligible and would not benefit from this project.

Why it matters

Potential benefit: If successful, the findings could help clinicians detect DIND earlier and guide more consistent diagnostic and treatment approaches, potentially reducing longer-term neurological disability.

How similar studies have performed: Previous observational registries have described symptomatic vasospasm and delayed cerebral ischemia but no single diagnostic gold standard or unified treatment guideline exists, so this real-world data collection follows precedent while addressing remaining gaps.

Eligibility criteria

Inclusion Criteria:

1. Age ≥ 18 years old
2. Primary diagnosis of subarachnoid hemorrhage due to rupture of a cerebral artery aneurysm confirmed by cerebral angiotomography or intracranial vessel angiography, requiring admission to the Intensive Care Unit (ICU).
3. Signature of the Informed Consent Form for participation in the study in accordance with local applicable regulations.

Exclusion Criteria:

1. Age \< 18 years old
2. Primary diagnosis of subarachnoid hemorrhage withouth a visible aneurysm, i.e., post-traumatic or caused by an arteriovenous malformation or bleeding from a brain tumor.

Where this trial is running

Beijing, Beijing Municipality

• Department of neurosurgery, Xuanwu hospital, Capital Medical University — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Study coordinator: Lidan Jiang

Conditions Aneurysmal Subarachnoid Hemorrhage